Adjuvant therapy for colorectal carcinoma

Anticancer Research

Volumn 22, Issue 4, 2002, Pages 2413-2418

  Kim, Ryungsa ^a   Yamaguchi, Yoshiyuki ^a   Toge, Tetsuya ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Adjuvant therapy; Chemotherapy; Colorectal carcinoma; Radiotherapy

Indexed keywords

CARMOFUR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; ORZEL; PICIBANIL; TEGAFUR;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; DRUG EFFICACY; HUMAN; JAPAN; META ANALYSIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS; NEOPLASM STAGING; RECTAL NEOPLASMS;

EID: 0036332866     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Cancer of the colon and rectum: Current concepts of aetiology and pathogenesis
2. Patterns of recurrence after curative resection of carcinoma of the colon and rectum
3. Chemotherapy in colorectal carcinoma
4. Colorectal cancer
5. Comparative efficacy of adjuvant chemotherapy in patients Dukes' B versus Dukes' C colon cancer: Results from for National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, C-04)
6. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
7. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma
8. Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: Five-year follow-up
9. Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer. Results from the Cooperative Project No. 7 Group of the Japanese Foundation for Multidisciplinary Treatment of Cancer
10. Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: Individual patient data meta-analysis of randomised trials
11. Adjuvant treatment of colorectal cancer
12. Improved survival with preoperative radiotherapy in resectable rectal cancer
13. Preoperative radiotherapy for resectable rectal cancer
14. The evaluation of low dose pre-operative x-ray therapy in the management of operable rectal cancer: Results of a randomly controlled trial
15. Genetic diagnosis of lymph-node metastasis in colorectal cancer
16. Identification of carcinoembryonic antigen-producing cells circulating in the blood of patients with colorectal carcinoma by reverse transcriptase-polymerase chain reaction
17. Molecular detection of circulating solid carcinoma cells in the peripheral blood: The concept of early systemic disease
18. Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in "node-negative" colorectal cancer
19. Blood dissemination of colonic epithelial cells during no-touch surgery for rectosigmoid cancer
20. No-touch isolation technique reduces intraoperative shedding of tumor cells into the portal vein during resection of colorectal cancer
21. CEA mRNA identification in peripheral blood is feasible for colorectal, but not for gastric or pancreatic cancer staging
22. Detection of ras gene mutations in peripheral blood of carcinoma patients using CD45 immunomagnetic separation and nested mutant allele specific amplification
23. Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and Me-CCNU following resection for carcinoma of the large bowel: A veterans administration surgical oncology group report
24. Surgical adjuvant therapy of large bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil
25. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project C-03
26. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04
27. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group Study
28. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid
29. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial
30. Comparison of fluorouracil with additional levamisole, high-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trail
31. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: Non-randomised comparison of weekly versus four-weekly schedules-less pain, same gain
32. Multicentre randomised trial of protracted versus infusion (PVI) 5 FU compared to 5 FU/folinic acid (5FU/FA) as adjuvant therapy for colorectal cancer
33. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: A prospective randomised trial
34. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project C-03
35. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
36. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
37. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
38. Improved survival with preoperative radiotherapy in resectable rectal cancer
39. Preoperative radiotherapy for resectable rectal cancer. A meta-analysis
40. Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin
41. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines
42. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line
43. Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin BNP 1100: Mechanisms and clinical implications
44. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
45. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
46. Effect of adding the topoisomerase I poison 7-ethy-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced cytotoxicity
47. Novel combinations with oxaliplatin
48. Oxaliplatin: A new agent for colorectal cancer
49. Computational methods for gene expression-based tumor classification
50. Coupled two-way clustering analysis of gene microarray data